---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-22-000006"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2022-02-16T23:59:59+00:00"
generated_at: "2026-06-27T07:39:33.861760+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Director Robert Califf resigns from Centessa board to become FDA Commissioner

## Summary
- Robert M. Califf, M.D., resigned from Centessa's Board effective Feb 16, 2022.
- Resignation due to his confirmation as incoming FDA Commissioner; not a disagreement.
- Dr. Califf is no longer a member of the Board or any committees.

## SEC filing metadata
- accession: 0001847903-22-000006
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2022-02-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000006/0001847903-22-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000006/cnta-20220216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-22-000006
- JSON: https://secwatch.observer/filing/0001847903-22-000006.json
- Plain text: https://secwatch.observer/filing/0001847903-22-000006.txt

## Key facts
- Executive change
  Robert M. Califf, M.D. resigned as Director at Centessa Pharmaceuticals plc.
  - Action: resigned
  - Role: Director
  source text: On February 16, 2022, Robert M. Califf, M.D., a member of the Board of Directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company” or “Centessa”), notified the Company of his resignation from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000006/0001847903-22-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.